IP Library Granted Patent US 8,309,162
Granted Patent B2
US 8,309,162 · App. 12/359,780 · Granted Nov 13, 2012

Implant surface with increased hydrophilicity

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,309,162
App. No.
12/359,780
Granted
Nov 13, 2012
Kind
B2
Abstract

A method of increasing the hydrophilicity of an implant to be implanted into living bone. The method comprises the act of depositing non-toxic salt residuals on the surface of the implant by exposing the surface to a solution including the non-toxic salts. The method further comprises the act of drying the implant.

Claims (38)

1. A method of increasing the hydrophilicity of an implant to be implanted into living bone, the method comprising the acts of:

depositing non-toxic sodium lactate salt residuals on the surface of the implant by immersing at least a portion of the implant in a solution including sodium lactate; and

drying the implant,

wherein the contact angle formed by a deionized water droplet on the surface of the implant ranges from about 5° to about 65°.

2. The method of claim 1 , wherein the solution is physiological saline solution or lactated Ringer's solution.

3. The method of claim 1 further comprising rinsing the implant prior to the act of drying the implant.

4. The method of claim 1 , wherein the non-toxic sodium lactate salt residuals are deposited as discrete residuals.

5. A method of increasing the hydrophilicity of an implant to be implanted into living bone, the method comprising the act of depositing non-toxic sodium lactate salt residuals on the surface of the implant by exposing the surface to a solution including the sodium lactate salt.

6. The method of claim 5 , wherein the solution is selected from the group consisting of physiological saline solution and lactated Ringer's solution.

7. The method of claim 5 , wherein the contact angle formed by a deionized water droplet on the surface of the implant ranges from about 5° to about 65°.

8. The method of claim 5 , wherein the non-toxic sodium lactate salt residuals are deposited as discrete residuals.

9. A method of increasing the hydrophilicity of an implant to be implanted into living bone, the method comprising the acts of:

depositing non-toxic sodium lactate salt residuals on the surface of the implant by exposing the surface to a solution including the sodium lactate salt; and

drying the implant.

10. The method of claim 9 , wherein the implant is made of a metal selected from the group consisting of tantalum, cobalt, chromium, titanium, stainless steel, or alloys thereof.

11. The method of claim 9 , wherein the implant is made from a material including ceramic.

12. The method of claim 9 , wherein the solution is selected from the group consisting of physiological saline solution and lactated Ringer's solution.

13. The method of claim 9 , further comprising, prior to the act of depositing the non-toxic sodium lactate salt residuals, roughening at least a portion of the implant surface to form a roughened surface.

14. The method of claim 13 , wherein the implant is made of titanium or titanium alloy and the act of roughening the implant surface comprises:

removing a native oxide layer from the implant surface; and

acid etching the resulting surface.

15. The method of claim 14 , wherein the native oxide is removed from a threaded bottom portion of the implant.

16. The method of claim 13 , wherein the act of roughening the implant surface creates irregularities having peak-to-valley heights not greater than about 20 microns.

17. The method of claim 13 , further comprising depositing discrete nanoparticles on the roughened surface by exposing the roughened surface to a solution including the nanoparticles, the nanoparticles comprising a material having a property that promotes osseointegration.

18. The method of claim 17 , wherein the discrete nanoparticles are deposited on the roughened surface by exposure to a solution comprising 2-methoxyethanol solvent and the nanoparticles.

19. The method of claim 17 , wherein the nanoparticles include hydroxyapatite nanocrystals.

20. The method of claim 17 , wherein the nanoparticles are on the order of about 20 nanometers to about 100 nanometers.

21. The method of claim 13 , further comprising, prior to the act of roughening, grit blasting at least a portion of the implant surface with a grit blast media.

22. The method of claim 21 , further comprising, prior to the act of roughening, removing residual grit blast media.

23. The method of claim 22 , wherein the act of removing residual grit blast media includes exposing the grit blasted portion of the implant surface to nitric acid.

24. The method of claim 21 , wherein the grit blast media is a resorbable grit blast media.

25. The method of claim 24 , wherein the resorbable grit blast media includes calcium phosphate.

26. The method of claim 21 further comprising, prior to the act of roughening, exposing the grit blasted portion of the implant surface to a first acid solution.

27. The method of claim 26 , wherein the first acid solution includes hydrofluoric acid.

28. The method of claim 9 , wherein a contact angle formed by a deionized water droplet on the surface of the implant ranges from about 5° to about 65°.

29. The method of claim 9 , wherein the implant is a dental implant.

30. The method of claim 9 , further comprising sterilizing the implant using gamma sterilization.

31. The method of claim 9 , wherein the non-toxic sodium lactate salt residuals are deposited as discrete residuals.

Assignments (5)
RELEASE OF SECURITY INTEREST Recorded Oct 20, 2025
From: JPMORGAN CHASE BANK, N.A.
To: BIOMET 3I, LLC; ZIMMER DENTAL INC.
Reel/Frame 073142/0312 →
SECURITY INTEREST Recorded Oct 20, 2025
From: BIOMET 3I, LLC; ZIMMER DENTAL INC.; IMPLANT CONCIERGE, LLC
To: GOLUB CAPITAL LLC, AS COLLATERAL AGENT
Reel/Frame 073142/0384 →
SECURITY INTEREST Recorded Mar 2, 2022
From: BIOMET 3I, LLC; EBI, LLC; ZIMMER BIOMET SPINE, INC.; ZIMMER DENTAL INC.
To: JPMORGAN CHASE BANK, N.A., AS ADMINISTRATIVE AGENT
Reel/Frame 059293/0213 →
RELEASE OF SECURITY INTEREST IN PATENTS RECORDED AT REEL 023505/ FRAME 0241 Recorded Nov 23, 2015
From: BANK OF AMERICA, N.A., AS ADMINISTRATIVE AGENT
To: LVB ACQUISITION, INC.; BIOMET, INC.; BIOMET 3I, LLC; BIOMET BIOLOGICS, LLC.; BIOMET EUROPE LTD.; BIOMET FAIR LAWN LLC; BIOMET HOLDINGS LTD.; BIOMET INTERNATIONAL LTD.; BIOMET LEASING, INC.; BIOMET MANUFACTURING CORPORATION; BIOMET MICROFIXATION, LLC; BIOMET ORTHOPEDICS, LLC; BIOMET SPORTS MEDICINE, LLC; BIOMET TRAVEL, INC.; BIOLECTRON, INC.; CROSS MEDICAL PRODUCTS, LLC; ELECTR-OBIOLOGY, LLC; EBI HOLDINGS, LLC; EBI, LLC; EBI MEDICAL SYSTEMS, LLC; BIOMET FLORIDA SERVICES, LLC; INTERPORE CROSS INTERNATIONAL, LLC; INTERPORE SPINE, LTD.; KIRSCHNER MEDICAL CORPORATION; IMPLANT INNOVATIONS HOLDINGS, LLC
Reel/Frame 037155/0082 →
SECURITY AGREEMENT Recorded Nov 12, 2009
From: LVB ACQUISITION, INC.; BIOMET, INC.; BIOMET 3I, LLC; BIOMET BIOLOGICS, LLC; BIOMET EUROPE LTD.; BIOMET FAIR LAWN LLC; BIOMET HOLDINGS LTD.; BIOMET INTERNATIONAL LTD.; BIOMET LEASING, INC.; BIOMET MANUFACTURING CORPORATION; BIOMET MICROFIXATION, LLC; BIOMET ORTHOPEDICS, LLC; BIOMET SPORTS MEDICINE, LLC; BIOMET TRAVEL, INC.; BIOLECTRON, INC.; CROSS MEDICAL PRODUCTS, LLC; ELECTRO-BIOLOGY, LLC; EBI HOLDINGS, LLC; EBI, LLC; EBI MEDICAL SYSTEMS, LLC; BIOMET FLORIDA SERVICES, LLC; INTERPORE CROSS INTERNATIONAL, LLC; INTERPORE SPINE, LTD.; KIRSCHNER MEDICAL CORPORATION; IMPLANT INNOVATIONS HOLDINGS, LLC
To: BANK OF AMERICA, N.A., AS ADMINISTRATIVE AGENT FOR THE SECURED PARTIES
Reel/Frame 023505/0241 →